The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation

10.1186/s12887-016-0611-0

Saved in:

Bibliographic Details
Main Authors:	Collins, C.T, Gibson, R.A, Makrides, M, McPhee, A.J, Sullivan, T.R, Davis, P.G, Thio, M, Simmer, K, Rajadurai, V.S, Ryan, P, Morris, S, Stark, M, Travadi, J, Wright, I, Tan, K, Holberton, J, Opie, G, Callander, I, Stack, J, Shein, D, Bellhouse, S, Bolisetty, S, Lui, K, Liley, H, Berry, M, Harris, D, Chua, M.C, Agarwal, P, The N3RO Investigative Te
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	2020
Subjects:	docosahexaenoic acid Article child hospitalization clinical protocol controlled study disease association drug effect drug efficacy enteric feeding female gestational age human infant lung dysplasia major clinical study male multicenter study newborn morbidity outcome assessment oxygen supply prematurity randomized controlled trial treatment duration clinical trial dietary supplement double blind procedure emulsion follow up newborn treatment outcome Bronchopulmonary Dysplasia Clinical Protocols Dietary Supplements Docosahexaenoic Acids Double-Blind Method Emulsions Enteral Nutrition Female Follow-Up Studies Humans Infant, Newborn Infant, Premature Male Treatment Outcome
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/181365
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-181365
record_format	dspace
spelling	sg-nus-scholar.10635-1813652023-10-31T21:15:20Z The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation Collins, C.T Gibson, R.A Makrides, M McPhee, A.J Sullivan, T.R Davis, P.G Thio, M Simmer, K Rajadurai, V.S Ryan, P Morris, S Stark, M Travadi, J Wright, I Tan, K Holberton, J Opie, G Callander, I Stack, J Shein, D Bellhouse, S Bolisetty, S Lui, K Liley, H Berry, M Harris, D Chua, M.C Agarwal, P The N3RO Investigative Te DUKE-NUS MEDICAL SCHOOL docosahexaenoic acid docosahexaenoic acid Article child hospitalization clinical protocol controlled study disease association drug effect drug efficacy enteric feeding female gestational age human infant lung dysplasia major clinical study male multicenter study newborn morbidity outcome assessment oxygen supply prematurity randomized controlled trial treatment duration clinical trial dietary supplement double blind procedure emulsion follow up lung dysplasia newborn prematurity treatment outcome Bronchopulmonary Dysplasia Clinical Protocols Dietary Supplements Docosahexaenoic Acids Double-Blind Method Emulsions Enteral Nutrition Female Follow-Up Studies Humans Infant, Newborn Infant, Premature Male Treatment Outcome 10.1186/s12887-016-0611-0 BMC Pediatrics 16 1 72 2020-10-27T10:42:17Z 2020-10-27T10:42:17Z 2016 Article Collins, C.T, Gibson, R.A, Makrides, M, McPhee, A.J, Sullivan, T.R, Davis, P.G, Thio, M, Simmer, K, Rajadurai, V.S, Ryan, P, Morris, S, Stark, M, Travadi, J, Wright, I, Tan, K, Holberton, J, Opie, G, Callander, I, Stack, J, Shein, D, Bellhouse, S, Bolisetty, S, Lui, K, Liley, H, Berry, M, Harris, D, Chua, M.C, Agarwal, P, The N3RO Investigative Te (2016). The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation. BMC Pediatrics 16 (1) : 72. ScholarBank@NUS Repository. https://doi.org/10.1186/s12887-016-0611-0 14712431 https://scholarbank.nus.edu.sg/handle/10635/181365 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	docosahexaenoic acid docosahexaenoic acid Article child hospitalization clinical protocol controlled study disease association drug effect drug efficacy enteric feeding female gestational age human infant lung dysplasia major clinical study male multicenter study newborn morbidity outcome assessment oxygen supply prematurity randomized controlled trial treatment duration clinical trial dietary supplement double blind procedure emulsion follow up lung dysplasia newborn prematurity treatment outcome Bronchopulmonary Dysplasia Clinical Protocols Dietary Supplements Docosahexaenoic Acids Double-Blind Method Emulsions Enteral Nutrition Female Follow-Up Studies Humans Infant, Newborn Infant, Premature Male Treatment Outcome
spellingShingle	docosahexaenoic acid docosahexaenoic acid Article child hospitalization clinical protocol controlled study disease association drug effect drug efficacy enteric feeding female gestational age human infant lung dysplasia major clinical study male multicenter study newborn morbidity outcome assessment oxygen supply prematurity randomized controlled trial treatment duration clinical trial dietary supplement double blind procedure emulsion follow up lung dysplasia newborn prematurity treatment outcome Bronchopulmonary Dysplasia Clinical Protocols Dietary Supplements Docosahexaenoic Acids Double-Blind Method Emulsions Enteral Nutrition Female Follow-Up Studies Humans Infant, Newborn Infant, Premature Male Treatment Outcome Collins, C.T Gibson, R.A Makrides, M McPhee, A.J Sullivan, T.R Davis, P.G Thio, M Simmer, K Rajadurai, V.S Ryan, P Morris, S Stark, M Travadi, J Wright, I Tan, K Holberton, J Opie, G Callander, I Stack, J Shein, D Bellhouse, S Bolisetty, S Lui, K Liley, H Berry, M Harris, D Chua, M.C Agarwal, P The N3RO Investigative Te The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation
description	10.1186/s12887-016-0611-0
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Collins, C.T Gibson, R.A Makrides, M McPhee, A.J Sullivan, T.R Davis, P.G Thio, M Simmer, K Rajadurai, V.S Ryan, P Morris, S Stark, M Travadi, J Wright, I Tan, K Holberton, J Opie, G Callander, I Stack, J Shein, D Bellhouse, S Bolisetty, S Lui, K Liley, H Berry, M Harris, D Chua, M.C Agarwal, P The N3RO Investigative Te
format	Article
author	Collins, C.T Gibson, R.A Makrides, M McPhee, A.J Sullivan, T.R Davis, P.G Thio, M Simmer, K Rajadurai, V.S Ryan, P Morris, S Stark, M Travadi, J Wright, I Tan, K Holberton, J Opie, G Callander, I Stack, J Shein, D Bellhouse, S Bolisetty, S Lui, K Liley, H Berry, M Harris, D Chua, M.C Agarwal, P The N3RO Investigative Te
author_sort	Collins, C.T
title	The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation
title_short	The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation
title_full	The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation
title_fullStr	The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation
title_full_unstemmed	The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation
title_sort	n3ro trial: a randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/181365
_version_	1781792488161280000

The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation

Similar Items